Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Muller & Phipps (India)BOM:501477 59 Buyback Yield % is 0.00 as of Jul. 29, 2026. GuruFocus rates BOM:501477 with a GF Score™ of 59/100 and a GF Value™ of ₹282.97 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 276 Healthcare Providers & Services companies, Muller & Phipps (India) ranks worse than 362318.48% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Muller & Phipps (India)'s Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Muller & Phipps (India) Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Muller & Phipps (India)'s Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Muller & Phipps (India)'s Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Muller & Phipps (India) (BOM:501477) has a Buyback Yield % of 0.00 as of Jul. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Muller & Phipps (India) and its competitors. According to the industry distribution chart, Muller & Phipps (India) ranks #999999 out of 276 companies in the Healthcare Providers & Services industry.
Is Muller & Phipps (India)'s Buyback Yield % too high?
Muller & Phipps (India)'s current Buyback Yield % is 0.00. Based on the distribution chart, Muller & Phipps (India) ranks #999999 out of 276 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Muller & Phipps (India) has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Muller & Phipps (India)'s Buyback Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Muller & Phipps (India) ranks #999999 out of 276 companies for Buyback Yield %. This places Muller & Phipps (India) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Muller & Phipps (India) and its competitors. Muller & Phipps (India)'s current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Muller & Phipps (India) stock overvalued right now?
Based on GuruFocus' analysis, Muller & Phipps (India) (BOM:501477) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹282.97, compared to a current price of ₹218.00 — trading 23% below its estimated fair value. The current Buyback Yield % is 0.00. Muller & Phipps (India)'s overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Muller & Phipps (India) (BOM:501477), the current Buyback Yield % is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Muller & Phipps (India) (BOM:501477) Overvalued in 2026?
Based on GuruFocus' analysis, Muller & Phipps (India) stock appears to be undervalued.
The current stock price of ₹218.00 is trading 23% below its estimated GF Value™ of ₹282.97.
GuruFocus considers Muller & Phipps (India) to be Modestly Undervalued.
Key valuation signals for BOM:501477:
Buyback Yield %: 0.00
GF Value™: ₹282.97 vs. price of ₹218.00 (23% below fair value)
No single metric tells the full story. See the BOM:501477 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Muller & Phipps (India) Ltd is engaged in the marketing of over-the-counter medical preparations and home care products. The operating segments of the company are Cosmetic/toiletry, Medicated preparation, Food Products, and Others, of which a majority of the revenue is derived from the Medical preparation segment. The company's product portfolio includes medicated dental products, ayurvedic skin ointment, and home care products. Its brand names include Cavisan, Cavidine, and Nixoderm.
59GF Score
Get the complete analysis for BOM:501477
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:501477 has been successfully added to your 
